Compugen | CGEN - Cash And Equivalent


Compugen reported $7.46M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Arca Biopharma USD 91.25M 25.86M Sep/2025
aTyr Pharma USD 6.15M 11.07M Sep/2025
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 5K 819K Sep/2025
Cara Therapeutics USD 20.65M 13.57M Jun/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 7.46M 985K Sep/2025
Immunic USD 35.13M 20.18M Sep/2025
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
Minerva Neurosciences USD 12.29M 2.96M Sep/2025
RedHill Biopharma USD 2.87M 1.75M Jun/2025
TherapeuticsMD 523K 89K Jun/2024